News

Oculogica receives ground-breaking patent to assess CTE via its eye-tracking technology

Oculogica’s patent enables expansion of its eye-tracking based technology to fulfill an unmet need in cannabis impairment detection

Keller Army Hospital at West Point, Children’s Hospital of Philadelphia, University of Wisconsin-Green Bay and AdHawk Microsystems will work with Oculogica to develop the wearable diagnostic

Oculogica, a medical device company and leader in concussion diagnosis and categorization, announced today the Therapeutic Goods Administration (TGA) of Australia granted approval to its EyeBOX technology. The test is for both pediatrics and adults. The technology is also patent protected in Australia.

Oculogica, the leader in non-invasive assessment of concussion, announces today the granting of U.S. Patent No. 10,863,902 by the U.S. Patent and Trademark Office. This patent protects Oculogica’s method and system for assessing glaucoma in a patient using a noninvasive eye tracking system.

Oculogica Founder, Dr. Uzma Samadani and CEO, Dr. Rosina Samadani, join the 11th annual list of women and men from such companies as Netflix, Google, and Patagonia, as well as institutions such as Johns Hopkins University and the ACLU of Massachusetts.

Last year, the FDA granted authorization for commercial use of the first tool that provides an objective diagnosis of concussions. Called EyeBox, it was developed by sisters Uzma and Rosina Samadani.

Watch our EyeBOX technology featured in Trevor Noah’s and Microsoft President Brad Smith’s discussion with Green Bay Packers President & CEO Mark Murphy.

Midwest Orthopaedics at Rush (MOR) is the first in Illinois to offer a new eye-tracking technology to more quickly identify a patient with ocular changes after a potential concussion or traumatic brain injury.

TitletownTech today announced it has invested in Oculogica, an innovative digital health company, by leading an $8 million round of funding that recently closed.